Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway

• Published in: EBioMedicine Vol. 28; no. C; pp. 80 - 89
• Main Authors: Pera, Benet, Krumsiek, Jan, Assouline, Sarit E., Marullo, Rossella, Patel, Jayeshkumar, Phillip, Jude M., Román, Lidia, Mann, Koren K., Cerchietti, Leandro
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.02.2018; Elsevier
• Subjects: Advanced Basic Science; Animals; Cell Line, Tumor; Cellular Reprogramming - drug effects; Choline - metabolism; Choline Kinase - metabolism; Choline pathway; DLBCL; Histone Deacetylase Inhibitors - pharmacology; Humans; Hydroxamic Acids - pharmacology; Indoles - pharmacology; Internal Medicine; Lymphoma, Large B-Cell, Diffuse - metabolism; Lymphoma, Large B-Cell, Diffuse - pathology; Lysine - metabolism; Male; Metabolome - drug effects; Metabolomics; Metabolomics - methods; Mice; Morpholines - pharmacology; Panobinostat; PI3K; Pyrimidines - pharmacology; Research Paper; Signal Transduction - drug effects; Xenograft Model Antitumor Assays; Panobinostat; Metabolomics; DLBCL; PI3K; Choline pathway

Despite the proven clinical antineoplastic activity of histone deacetylase inhibitors (HDACI), their effect has been reported to be lower than expected in B-cell lymphomas. Traditionally considered as “epigenetic drugs”, HDACI modify the acetylation status of an extensive proteome, acting as general...